Sanofi shares phase 2b results for dermatitis treatment
Betsy Goodfellow | March 12, 2024 | News story | Research and Development | Dermatology, Sanofi, amlitelimab, atopic dermatitis, clinical trial, dermatitis
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study of amlitelimab for adult patients with moderate to severe atopic dermatitis (AD) who previously responded to amlitelimab and continued treatment.
The trial showed sustained improvement of signs and symptoms of AD for 28 weeks, as well as high responder rates also being observed in participants who were taken off the drug.
The safety profile of amlitelimab remained consistent with what was reported in part 1 of the study, with the drug being well-tolerated and no new safety concerns being identified.
These results were presented at the American Academy of Dermatology (AAD) 2024 Conference which took place in San Diego, US, and support the quarterly dosing of the drug at 250mg and 500mg, which is now being investigated in a larger phase 3 trial.
Naimish Patel MD, head of global development, immunology and inflammation at Sanofi, commented: “It’s unprecedented to see this type of durability of clinical response, which we believe could be very meaningful to patients and is the reason why we selected an every 12-week dosing regimen in the AD pivotal program. AD is a chronic, lifelong disease, which means we must strive to provide a portfolio of solutions to patients that matches their individual needs and puts as little burden on them as possible. We are also moving with speed in our exploration of amlitelimab’s potential in five other chronic inflammatory diseases, including asthma, hidradenitis suppurativa, scleroderma, coeliac disease and alopecia. In addition, we are exploring six other innovative mechanisms of action (MOAs) in eight dermatologic indications underscoring our commitment to patients with high unmet medical needs.”
Betsy Goodfellow
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …
How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …
